NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,793.00+₹32.00 (+1.82%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 12.5% below the high.
Loading market information…
NSE · LINCOLN.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:21 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Lincoln Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 32.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Lincoln Pharmaceuticals Limited’s forward annual dividend is ₹1.80 per share, paid annual. The forward yield is 0.35% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lincoln Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of medical needs, including dermatological, gynecological, gastrointestinal, and otological conditions. The company also specializes in phosphodiesterase type 5 inhibitors and general anesthetics. Further expanding its therapeutic reach, Lincoln provides treatments for common ailments like coughs, colds, and allergies, alongside anti-asthmatics. Other key product categories include sterile ophthalmic solutions (eye drops and ointments), anti-malarial drugs, and a range of vitamins, minerals, and antioxidants. The portfolio is further diversified with anti-bacterial, anti-viral, and anti-fungal agents; pain relief and fever reduction medications (analgesics and anti-pyretics); and specialized drugs for mental health (anti-psychotics, anti-convulsants, anti-depressants) and diabetes (anti-diabetics). Cardiovascular health is addressed with anti-hypertensives and diuretics, while gastrointestinal issues are targeted with anti-diarrheals, anti-spasmodics, and laxatives. Additionally, the company offers branded generic pharmaceuticals.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:22 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₹1.47B+58.24% vs estimate |
| Q2 2025 | Nov 14, 2024 | ₹13.15+115.57% vs estimate | ₹1.61B+74.07% vs estimate |
|---|
| Q1 2025 | Aug 8, 2024 | ₹11.82+93.77% vs estimate | ₹1.47B+59.03% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,793.00+₹32.00 (+1.82%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 12.5% below the high.
₹9,809.00+₹145.00 (+1.5%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.3% below the high.
₹378.35-₹31.45 (-7.67%)
Ind-Swift Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 11.31% below the high.
₹956.80+₹10.30 (+1.09%)
Sakar Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 22.2% below the high.
₹1,281.90-₹7.40 (-0.57%)
Venus Remedies Limited’s quoted price sits in the upper half of its reported 52-week range, 37.29% below the high.
₹98.11+₹0.59 (+0.61%)
Themis Medicare Limited’s quoted price sits in the lower half of its reported 52-week range, 30.22% below the high.
₹148.90-₹1.36 (-0.91%)
Max India Limited’s quoted price sits in the lower half of its reported 52-week range, 32.32% below the high.
₹179.41-₹2.52 (-1.39%)
Wanbury Limited’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
